FY2025 Earnings Forecast for ANRO Issued By Chardan Capital

Alto Neuroscience, Inc. (NYSE:ANRO) – Stock analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Alto Neuroscience in a research report issued to clients and investors on Tuesday, September 30th. Chardan Capital analyst R. Li expects that the company will post earnings of ($2.45) per share for the year. Chardan Capital has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. Chardan Capital also issued estimates for Alto Neuroscience’s FY2026 earnings at ($1.80) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Alto Neuroscience in a research report on Monday, August 18th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.80.

Alto Neuroscience Stock Performance

ANRO stock opened at $4.44 on Friday. Alto Neuroscience has a one year low of $1.60 and a one year high of $15.04. The firm has a 50-day simple moving average of $3.60 and a two-hundred day simple moving average of $2.84. The company has a debt-to-equity ratio of 0.18, a quick ratio of 18.43 and a current ratio of 18.43. The firm has a market cap of $120.10 million, a price-to-earnings ratio of -1.86 and a beta of 2.00.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08).

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Armistice Capital LLC boosted its position in Alto Neuroscience by 1.5% in the second quarter. Armistice Capital LLC now owns 1,624,000 shares of the company’s stock valued at $3,573,000 after buying an additional 24,000 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Alto Neuroscience by 9.9% during the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after purchasing an additional 84,417 shares during the last quarter. AWM Investment Company Inc. boosted its holdings in Alto Neuroscience by 31.1% in the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock valued at $1,948,000 after purchasing an additional 214,153 shares during the last quarter. Peapod Lane Capital LLC acquired a new stake in Alto Neuroscience during the 2nd quarter worth about $613,000. Finally, Nuveen LLC acquired a new position in shares of Alto Neuroscience in the 1st quarter valued at about $302,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.